

EURO-CHOLANGIO-NET

and the fight against cholangiocarcinoma (CCA)

The frequent misdiagnosis and increasing prevalence of CCAs suggest there is an underestimation of this health problem.

EURO-CHOLANGIO-NET represents a pan-European interdisciplinary co-operative network, joining stakeholders, scientists, clinicians, industry partners, and others in the fight for better understanding and treating this disease.

Cancer of the biliary tree is one of the deadliest cancers → most frequent cause of cancer metastases of unknown origin

Intrahepatic (iCCA)

Location
Bile ductules-segmental ducts

Incidence
10-20%

Risk factors
Obesity, diabetes, cirrhosis, viral hepatitis

Perihilar (pCCA)

Location
Hepatic ducts

Incidence
50-60%


Risk factors
Primary sclerosing cholangitis, lithiasis

Distal (dCCA)


Location
Common bile duct

Incidence
20-30%

Risk factors
Diabetes, lithiasis



General risk factors



Most frequent symptoms

Asymptomatic in early stages

Painless jaundice (pCCA and dCCA)

Abdominal pain, fatigue, indigestion (iCCA)

Incidence (inhabitants per year)

Increasing in Europe **0.3–6 / 100 000**

South Korea, China, and Thailand **>6 / 100 000**

Survival: <20% 5-year survival rate

Surgery (potential curative therapy) **20-30% of cases**

Systemic anticancer treatment (not operable) **70-80% of cases**

Cisplatin/ gemcitabine chemotherapy OS: 10%

Cisplatin/ gemcitabine chemotherapy + durvalumab immunotherapy OS: 24%

Molecular profiling of tumours at diagnosis (targeted therapies) OS: 50%

OS: Overall survival at 2 years

Global mortality

1–6 / 100 000 inhabitants per year

Learn more at: <https://eurocholangionet.eu/>